Objective: Potential of combined androgen blockade (CAB) has not been explored extensively in Chinese males with prostate cancer (PCa). Therefore, this study evaluated the 2-year prostate-specific antigen (PSA) recurrence rate and quality of life (QoL) in patients with high-risk localized and locally advanced PCa receiving adjuvant hormone therapy (HT) after radical prostatectomy (RP).
Methods: This prospective, multicenter, observational study conducted in 18 centers across China enrolled patients with high-risk factor (preoperative PSA>20 ng/mL or Gleason score >7) or locally advanced PCa. Different adjuvant HT were administered after RP according to investigator's decision in routine clinical practice. Relationship of baseline and postoperative characteristics was assessed with recurrence rate. PSA recurrence rate and Functional Assessment of Cancer Therapy-Prostate (FACT-P) QoL scores were recorded at 12 months and 24 months. Kaplan-Meier analysis was used to construct the PSA recurrence rate during follow-up.
Results: A total of 189 patients (mean age: 66.9 +/- 6.5 years) were recruited, among which 112 (59.3%) patients showed serum PSA>20 ng/mL preoperatively. The highest postoperative pathological advancement noticed was from clinical T2 (cT2) to pathological T3 (pT3) (43.9%) stage. The majority of the patients (66.1%) received CAB as adjuvant HT, for a median duration of 20.0 months. The least recurrence (15.2%) was noticed in patients treated with CAB, followed by those treated with luteinizing hormone-releasing hormone agonist (LHRHa) (16.1%), and antiandrogen (19.0%), with non-significant difference noted among the groups. None of the baseline or postoperative characteristics was related with PSA recurrence in our study. The 24-month FACT-P QoL score of 119 patients treated for >12 months showed significant improvement above baseline compared with those treated for <= 12 months.
Conclusions: Adjuvant CAB therapy after RP showed reduction trend in 2-year PSA recurrence rate in high-risk Chinese patients with localized and locally advanced PCa, compared with adjuvant anti-androgens (AA) or LHRHa therapy. Further long-term therapy (>12 months) significantly improved QoL compared to short-term HT therapy, suggesting the beneficial effect of long-term CAB therapy in improving QoL.
[1]Fudan Univ, Shanghai Canc Ctr, Dept Urol, Shanghai 200032, Peoples R China;
[2]Jiangsu Prov Hosp, Dept Urol, Nanjing 210029, Jiangsu, Peoples R China;
[3]Peking Univ, Hosp 3, Dept Urol, Beijing 100191, Peoples R China;
[4]Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Urol, Hangzhou 310009, Zhejiang, Peoples R China;
[5]Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Urol, Hangzhou 310003, Zhejiang, Peoples R China;
[6]Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Urol, Shanghai 200127, Peoples R China;
[7]Sichuan Univ, West China Hosp, Dept Urol, Chengdu 610041, Sichuan, Peoples R China;
[8]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Urol, 1095 Jie Fang Ave, Wuhan 430030, Hubei, Peoples R China;
[9]Peking Univ, Shougang Hosp, Dept Urol, 9 Jinyuanzhuang Rd, Beijing 100144, Peoples R China
(8.0+极速模式)